Bronchiectasis in older patients with chronic obstructive pulmonary disease: Prevalence, diagnosis and therapeutic management

Drugs and Aging

Volumn 30, Issue 4, 2013, Pages 215-225

  Whitters, Deborah ^a   Stockley, Robert A ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CLARITHROMYCIN; CORTICOSTEROID; ERYTHROMYCIN; FLUTICASONE; FORMOTEROL; INTERLEUKIN 1; INTERLEUKIN 8; LEUKOTRIENE B4; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY OBSTRUCTION; AIRWAY REMODELING; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM ISOLATION; BRONCHIECTASIS; CELL COUNT; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; FORCED EXPIRATORY VOLUME; GENETIC SUSCEPTIBILITY; HAEMOPHILUS INFLUENZAE; HEARING IMPAIRMENT; HOSPITAL ADMISSION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INCIDENTAL FINDING; INNATE IMMUNITY; LIVER FUNCTION TEST; LUNG FUNCTION; LUNG INFECTION; LUNG TUBERCULOSIS; MEASLES; META ANALYSIS; MORAXELLA CATARRHALIS; MUCOCILIARY CLEARANCE; PERTUSSIS; PHENOTYPE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TISSUE INJURY;

EID: 84876908000     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0053-4     Document Type: Review

References (79)

1. Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12(4):205-9. (Pubitemid 41098340)
2. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28(3):523-32. (Pubitemid 44794666)
3. O'Brien C, Guest PJ, Hill SL, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55:635-42. (Pubitemid 30468217)
4. Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011;140(5):1130-7.
5. Cole P, Wilson R. Host microbial interrelationships in respiratory infection. Chest. 1989;95:217S-21S. (Pubitemid 19088589)
6. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162:1277-84.
7. Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guidelines for non CF bronchiectasis. Thorax. 2010;65:i1-58.
8. O'Donnell AE. Bronchiectasis in patients with COPD: a distinct COPD phenotype? Chest. 2011;140(5):1107-8.
9. Wedzicha JA, Hurst JR. Structural and functional co-conspirators in chronic obstructive pulmonary disease exacerbations. Proc Am Thor Soc. 2007;4(8):602-5. (Pubitemid 350291621)
10. Devereux G. ABC of chronic obstructive pulmonary disease. Definition, epidemiology and risk factors. BMJ. 2006;332:1142-4. (Pubitemid 44480883)
11. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
12. Patel IS, Vlahos I, Wilkinson TMA, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(4):400-7. (Pubitemid 39214614)
13. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(5 Suppl):121S-6S. (Pubitemid 34497328)
14. Murray CJL, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science. 1996;274(5288):740-3. (Pubitemid 26398244)
15. Crofton J, Douglas A, editors. Respiratory diseases. 3rd ed. Oxford: Blackwell Science Ltd; 1981. p. 417-30.
16. Saynajakangas O, Keistinen T, Tuuponen T, et al. Bronchiectasis in Finland: trends in hospital treatment. Respir Med. 1997;91(7):395-8. (Pubitemid 27308190)
17. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Resp Med. 2010;104(7):981-5.
18. Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalisations in the United States, 1993-2006. Chest. 2010;138(4):944-9.
19. Smith IE, Jurriaans E, Diederich S, et al. Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax. 1996;51(9):914-8. (Pubitemid 26289031)
20. Jones DK, Godden D, Cavanage P. Alpha 1 antitrypsin deficiency presenting as bronchiectasis. Br J Dis Chest. 1985;79(3):301-4. (Pubitemid 15063932)
21. Dowson LJ, Guest PJ, Stockley RA. The relationship of chronic sputum expectoration to physiological, radiologic, and health status characteristics in alpha(1)-antitrypsin deficiency (PiZ). Chest. 2002;122(4):1247-55. (Pubitemid 35339537)
22. Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2007;176(12):1215-21. (Pubitemid 350256475)
23. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117(6):1638-45. (Pubitemid 30413357)
24. Wilson R. Bacteria, antibiotics and COPD. Eur Resp J. 2001;17(5):995-1007. (Pubitemid 32600350)
25. Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(8):853-60. (Pubitemid 351600663)
26. Martinez-Garcia MA, Soler-Cataluńa JJ, Perpińá- Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132:1565-72. (Pubitemid 350156014)
27. Wilson R. Outcome predictors in bronchitis. Chest. 1995;108(2):53s-7s.
28. Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis. 1993;147(2):301-6. (Pubitemid 23044899)
29. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis cellular and molecular mechanisms. Eur Respir J. 2008;31(2):396-406.
30. Sharafkhaneh A, Hanania NA, Kim V. Pathogenesis of emphysema: from the bench to the bedside. Proc Am Thorac Soc. 2008;5(4):475-7. (Pubitemid 351669173)
31. Cole PJ. Inflammation: a two edged sword - the model of bronchiectasis. Eur J. Respir Dis Suppl. 1986;147:6-15. (Pubitemid 16017382)
32. Martinez Garcia MA, Perpina-Tordera M, Roman-Sanchez P, et al. Quality of life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128(2):739-45. (Pubitemid 41140504)
33. Roberts HR, Wells AU, Milne DG, et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax. 2000;55(3):198-204. (Pubitemid 30245969)
34. King P, Holdsworth SR, Freezer NJ, et al. Outcome in adult bronchiectasis. COPD. 2005;2(1):27-34. (Pubitemid 40776219)
35. King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411-9.
36. Elborn JS, Johnstone B, Allen F, et al. Inhaled steroids in patients with bronchiectasis. Respir Med. 1992;86(2):121-4.
37. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a twelve month study. Thorax. 2005;60(3):239-43. (Pubitemid 40380285)
38. Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, et al. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006;100(9):1623-32. (Pubitemid 44089352)
39. Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev. 2001;(4):CD002155.
40. Franco F, Sheikh A, Greenstone M. Short-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev. 2003;(3):CD003572.
41. Tashkin DP, Celli B, Senn S, et al. A four year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-54.
42. Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(9):991-8.
43. Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med. 2001;164(9):1628-32. (Pubitemid 33124150)
44. King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs. 2007;67(7):965-74. (Pubitemid 46744473)
45. Sin DD, Man SF. Steroids in COPD: still up in the air? Eur Respir J. 2010;35(5):949-51.
46. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641-7.
47. Singh S, Loke YK. Risk of pneumonia associated with long term use of inhaled corticosteroids in COPD: a critical review and update. Curr Opin Pulm Med. 2010;16(2):118-22.
48. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Resp Crit Care Med. 2008;177(1):19-26.
49. National Institute for Health and Clinical Excellence. Clinical guideline 101 - chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care (update of NICE clinical guideline 12). London: National Institute for Health and Clinical Excellence. June 2010. http://guidance.nice.org.uk/CG101. Accessed 17 Sep 2012.
50. Kapur N, Bell S, Kolbe J et al. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009; 21(1):CD000996.
51. Tsang KW, Pak-Leung HO, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158(3):723-7. (Pubitemid 28449432)
52. Martinez-Garcia MA, Soler-Cataluna JJ, Catalan-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012;141(2):461-8.
53. Antoniu SA. New therapeutic options in the management of COPD - focus on roflumilast. Int J Chron Obstruct Pulmon Dis. 2011;6:147-55.
54. Gamble E, Grootendorst DC, Brightling CE, et al. Anti-inflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168(8):967-82. (Pubitemid 37267176)
55. Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.
56. Foreman MG, DeMeo DL, Hersh CP, et al. Clinical determinants of exacerbations in severe, early-onset COPD. Eur Respir J. 2007;30(6):1124-30. (Pubitemid 351194759)
57. Schenkein JG, Nahm MH, Dransfield MT. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest. 2008;133(3):767-74. (Pubitemid 351367387)
58. Rubins JB, Puri AK, Loch J, et al. Magnitude, duration, quality and function of pneumococcal vaccine responses in elderly adults. J Infect Dis. 1998;178(2):431-40. (Pubitemid 28347925)
59. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999;29(2):281-8. (Pubitemid 29380185)
60. Poole P, Chacko EE, Wood-Baker R, et al. Influenzae vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;25(1):CD002733.
61. Kang I, Hong MS, Nolasco H, et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol. 2004;173(1):673-81. (Pubitemid 38797398)
62. World Health Organisation. WHO position paper on Haemophilus influenza type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record.). Wkly Epidemiol Rec. 2006;81(47):445-52.
63. McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine. 2005;23(Suppl 1):S10-25. (Pubitemid 41019629)
64. Woodhead M. New guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2011;38(6):1250-1.
65. Itkin IH, Menzel ML. The use of marolide antibiotic substances in the treatment of asthma. J Allergy. 1970;45(3):146-62.
66. Kudoh S, Uetake T, Hagiwara K. et al Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis [in Japanese with English abstract]. Jpn J Thorac Dis. 1987;25:632-42. (Pubitemid 17141772)
67. Tateda K, Ishii Y, Kimura S, et al. Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery? J Infect Chemother. 2007;13(6):357-67. (Pubitemid 350308158)
68. Smith DJ, Chang AB, Bell SC. Anti-inflammatory therapies in bronchiectasis. Eur Respir Mon. 2011;52:223-38.
69. Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004;125(2 Suppl):41S-50S.
70. Gorrini M, Lupi A, Viglio S, et al. Inhibition of human neutrophil elastase by erythromycin and flurithromycin, two macrolide antibiotics. Am J Respir Cell Mol Biol. 2001;25(4):492-9. (Pubitemid 33037682)
71. Cymbala AA, Edmonds LC, Bauer MA, et al. The disease modifying effects of twice weekly azithromycin in patients with bronchiectasis. Treat Respir Med. 2005;4(2):117-22. (Pubitemid 40613959)
72. Tsang KW, Ho PI, Chan KN. A pilot study of low dose erythromycin in bronchiectasis. Eur Respir J. 1999;13(2):361-4. (Pubitemid 29086834)
73. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-98.
74. Basyigit I, Yildiz F, Ozkara SK, et al. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother. 2004;38(9):1400-5. (Pubitemid 39100191)
75. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139-47.
76. Sapey E, Stockley RA. COPD exacerbations 2: aetiology. Thorax. 2006;61(3):250-8.
77. El Moussari R, Roede BM, Speelman P, et al. Short course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax. 2008;63(5):415-22. (Pubitemid 351692349)
78. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax. 2002;57(9):759-64. (Pubitemid 34984972)
79. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung. 2006;35(1):58-65. (Pubitemid 43106636)